

AWARD NUMBER: W81XWH-19-1-0848

TITLE: Novel Topical Antibiotic Therapy to Reduce Infection After Operative Treatment of Fractures at High Risk of Infection: TOBRA-A Multicenter RCT

PRINCIPAL INVESTIGATOR: Robert V. O'Toole, MD

CONTRACTING ORGANIZATION: University of Maryland, Baltimore, MD

REPORT DATE: October 2023

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Development Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE October 2023		2. REPORT TYPE Annual		3. DATES COVERED 30Sep2022-29Sep2023	
4. TITLE AND SUBTITLE Novel Topical Antibiotic Therapy to Reduce Infection After Operative Treatment of Fractures at High Risk of Infection: TOBRA-A Multicenter RCT				5a. CONTRACT NUMBER W81XWH-19-1-0848	
				5b. GRANT NUMBER OR180184	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Robert V. O'Toole, MD E-Mail: ROtoole@som.umaryland.edu				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Department of Orthopaedic Surgery University of Maryland School of Medicine, Baltimore 22 S. Greene St. Shock Trauma, Baltimore, MD 21201				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Development Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT Background: Infection after treatment of high-energy military fractures is very common and continues to cause significant morbidity. Recently, a study showing the use of local vancomycin powder around metal hardware used to treat these at-risk fractures results in a reduced risk of infection. The powder is thought to create a kill zone around the metal, prevent bacterial colonization, and therefore reduce the rate of postoperative infection. Specific Aims: Our primary specific aim is to demonstrate that the infection rate (defined by CDC criteria) is lower in patients with at-risk fractures treated with standard of care as well as local vancomycin and tobramycin than patients treated with standard of care and vancomycin alone. Additional specific aims include investigation of the potential development of antibiotic resistance and examining bacterial sensitivities in patients who become infected in the treatment group and comparing the proportion of additional complications such as wound dehiscence and nonunion. Study Design: The proposed study is a multi-center prospective open label randomized controlled trial. The study will accumulate patients from 50 core civilian and 1 military center to ensure generalizability. The study group will be a set of tibial plateau and pilon fractures previously shown to be at high risk of infection treated with plate and screw fixation. 1900 participants (950 per treatment arm) will be enrolled from METRC trauma centers over 24 months. Participants will be recruited during hospitalization for the initial injury. Military Benefit and Clinical Impact: Infection is a very common and serious complication associated with the treatment of high-energy military extremity trauma. Fixation of fractures in these injuries involves the use of metal implants. Plates and screws become colonized with bacteria and lead to high rates of infection that are not treated well with intravenous antibiotics. If the proposed study demonstrated the utility of this technology, it would have a dramatic effect on reducing the morbidity associated with extremity trauma. Further, a positive result could revolutionize the approach to prophylaxis against surgical site infection after orthopaedic fracture care in both the military and civilian arenas by moving the field toward technologies that focus on local antibiotics associated with the implanted devices. As of 9/10/23, 808 participants have been enrolled. There are 29 sites actively screening/enrolling and other participating sites' status can be found in the attachment. The study team is actively engaged with the rest of the participating sites on the administrative approval process.					
15. SUBJECT TERMS Surgical site infection (SSI); vancomycin; tobramycin; topical antibiotics; tibial plateau; pilon; fracture fixation; orthopaedic surgery; trauma; METRC					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT Unclassified	18. NUMBER OF PAGES 22	19a. NAME OF RESPONSIBLE PERSON USAMRDC
a. REPORT Unclassified	b. ABSTRACT Unclassified	c. THIS PAGE Unclassified			19b. TELEPHONE NUMBER (include area code)

TABLE OF CONTENTS

	<u>Page</u>
1. Introduction	4
2. Keywords	4
3. Accomplishments	4-7
4. Impact	8
5. Changes/Problems	9-10
6. Products	10-11
7. Participants & Other Collaborating Organizations	12-14
8. Special Reporting Requirements	15
9. Appendix – Site Status	15

1. INTRODUCTION: *Narrative that briefly (one paragraph) describes the subject, purpose, and scope of the research.*

This study will build upon the success of the VANCO study (Contract Number: W81XWH-10-2-0134, FDA IND #119891) which enrolled 980 patients into a randomized controlled trial investigating topical Vancomycin powder versus no powder in patients having plate and screw fixation for fractures at risk of surgical site infection. The PI, Co-PI and most of the research team that led the VANCO study will serve similar roles in the current study. The proposed study design is a pragmatic, prospective, randomized controlled trial comparing deep surgical site infection rates in patients treated with either local Vancomycin powder or local Vancomycin and Tobramycin powders at the time of fracture fixation (in addition to standard of care). This study design will provide the highest quality evidence to investigate our hypothesis that the use of local Vancomycin and Tobramycin powders will be effective at decreasing deep surgical site infection in these at-risk patients. Participants (950 per treatment arm) will be enrolled from METRC trauma centers over a 24-month period and followed for 12 months following definitive fracture fixation surgery. Participants will be recruited during hospitalization for the initial injury.

2. KEYWORDS: *Provide a brief list of keywords (limit to 20 words).*

Surgical site infection (SSI); vancomycin; tobramycin; topical antibiotics; tibial plateau; pilon; fracture fixation; orthopaedic surgery; trauma; METRC

3. ACCOMPLISHMENTS: *The PI is reminded that the recipient organization is required to obtain prior written approval from the awarding agency grants official whenever there are significant changes in the project or its direction.*

What were the major goals of the project?

The specific aims of the study are as follows:

- Specific Aim 1: Compare the proportion of deep surgical site infections (SSI) of the study injury within 365 days of definitive fracture fixation surgery in patients allocated to receive a combination of local Vancomycin and Tobramycin powders compared to patients allocated to local Vancomycin powder.
- Specific Aim 2: A series of sensitivity analyses will be conducted to look at alternative measures of deep SSI under Specific Aim 1. These sensitivity analyses will consider the following alternative endpoints of deep SSI: infection by gram-negative bacteria, infection by gram-positive bacteria, polymicrobial pathogenic infections, culture-negative infections, and cellulitis/skin infections.
- Specific Aim 3: To compare the safety of treatment with a combination of local Vancomycin and Tobramycin versus Vancomycin powder alone as measured by the proportion of antibiotic resistance in each arm.

The tasks and milestones set forth to meet the aims of the project, as stated in the approved scope of work, are shown in the table below. Items not yet completed and marked with an asterisk (*) in the

status column below have additional information specifically addressed in other sections of this report.

<u>Tasks and Milestones</u>	<u>Timeline</u>	<u>Status</u>
Major Task 1: Study Initiation		
• Submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA)	Oct 2019-Nov 2019	Completed
• Refine eligibility criteria, exclusion criteria, and screening protocol	Oct 2019-Nov 2019	Completed
• Finalize consent form & human subject protocol	Oct 2019-Nov 2019	Completed
• Develop case report forms (CRFs) for data capture, program, and pilot test REDCap	Oct 2019-Dec 2019	Completed
• Coordinate with Sites for IRB protocol submission	Oct 2019-Dec 2022	Started (95%)*
• Coordinate with Sites for IRB review	Oct 2019-Dec 2022	Started (90%)*
• Coordinate with Sites for Military 2nd level IRB review (ORP/HRPO)	Oct 2019-Dec 2022	Started (75%)*
• <i>Milestone:</i> Local IRB approval at MCC and UMD	Mar 2021	Completed
• <i>Milestone:</i> HRPO approval for all protocols and local IRB approval through required participating sites	June 2021-Dec 2021	Started (75%)*
• <i>Milestone:</i> FDA IND Approval	Mar 2020	Completed
Major Task 2: Training Research Staff		
• Develop and conduct training for Research Coordinators on procedures for screening and consenting patients, study procedures, and data collection/reporting.	Feb 2020-May 2020	Completed
• Certify sites to begin screening and enrolling patients	May 2021-Dec 2022	Started (75%)*
• Conduct study initiation calls with each site to ensure procedures are in place	Feb 2020-Dec 2022	Started (85%)*
• <i>Milestone:</i> Research Staff Trained	June 2021	Started (85%)*
Major Task 3: Conduct Study		
• Clinical site Research Coordinators will screen and enroll eligible study patients	May 2021-April 2023	Started*
• Generate and distribute monthly enrollment and follow-up reports; provide ongoing training and support to address problems with enrollment as they are identified	July 2021-Mar 2023	Started
• Generate and distribute data quality reports to monitor data completeness; check for errors and inconsistencies	March 2022-July 2023	Started

• <i>Milestone:</i> The first patient enrolled at the principal investigator's site. • <i>Milestone:</i> All patients enrolled • <i>Milestone:</i> All patient follow up complete	June 2021 Mar 2023 Mar 2024	Completed
Major Task 4: Outcome Adjudication		
• Develop data presentation profiles of cases ready for the adjudication • Convene adjudication committee to determine study outcomes for records that have been fully completed. • <i>Milestone:</i> Outcome Adjudication Completed	Jan 2022-Jan 2023 Jan 2022-May 2024 May 2024	Started Started
Major Task 5: Data Analysis and Report Writing		
• Develop final analysis files • Conduct analysis and write final reports and peer-reviewed publications • Disseminate results published in peer-reviewed journals and presentation at professional and scientific meetings • <i>Milestone:</i> Report findings from the final analysis	Jan 2024-Jul 2024 Mar 2024-Sep 2024 Mar 2024-Sep 2024 Sep 2024	

What was accomplished under these goals?

For this reporting period describe 1) major activities; 2) specific objectives; 3) significant results or key outcomes, including major findings, developments, or conclusions (both positive and negative); and/or 4) other achievements. Include a discussion of stated goals not met. Description shall include pertinent data and graphs in sufficient detail to explain any significant results achieved. A succinct description of the methodology used shall be provided. As the project progresses to completion, the emphasis in reporting in this section should shift from reporting

As of September 10, 2023, 2235 patients were screened, and 808 participants have been enrolled. Please refer to the end of the report (pg 16-21) for the screening/enrollment and follow-up progress of the study. Enrollment is close to enrollment goal per unit time but the overall enrollment is delayed over a year because of COVID issues, delay in contract, and the problems related to the central IRB requirement.

There are twenty nine actively screening and enrolling patients out of the thirty-six sites certified. There are four additional sites with HRPO approval waiting for certification to begin screening activity, and 2 sites preparing for HRPO submission. We are continuing to work through the process of reliance agreements, local cede reviews, and central IRB submissions with other participating sites. There are 3 sites waiting for Pearl sIRB approval, and 6 sites waiting for local IRB approval. Refer to the attached appendix for the detailed list of the participating site status.

The coordinating center is sending out regular summary reports and data queries each month. Also, monthly site research coordinator meetings have been held since February 2022. The adjudication committee is reviewing the early discontinuation and potential primary outcome cases in real-time. Additional communications with sites are in place via emails or phone calls to address any questions or issues.

The prime site received official memo from DoD regarding NCE and the study team is sending out extensions to all participating sites.

What opportunities for training and professional development has the project provided?

If the project was not intended to provide training and professional development opportunities or there is nothing significant to report during this reporting period, state “Nothing to Report.”

Describe opportunities for training and professional development provided to anyone who worked on the project or anyone who was involved in the activities supported by the project. “Training” activities are those in which individuals with advanced professional skills and experience assist others in attaining greater proficiency. Training activities may include, for example, courses or one-on-one work with a mentor. “Professional development” activities result in increased knowledge or skill in one’s area of expertise and may include workshops, conferences, seminars, study groups, and individual study. Include participation in conferences, workshops, and seminars not listed under major activities.

Nothing to report

How were the results disseminated to communities of interest?

If there is nothing significant to report during this reporting period, state “Nothing to Report.”

Describe how the results were disseminated to communities of interest. Include any outreach activities that were undertaken to reach members of communities who are not usually aware of these project activities, for the purpose of enhancing public understanding and increasing interest in learning and careers in science, technology, and the humanities.

Nothing to report

What do you plan to do during the next reporting period to accomplish the goals?

If this is the final report, state “Nothing to Report.”

Describe briefly what you plan to do during the next reporting period to accomplish the goals and objectives.

The next reporting period will be focused on enrollment, data collection, and gaining the necessary approvals to begin enrollment at the rest of the participating sites. Key activities will include:

1. Enrollment: We will continue enrolling and anticipate the pace to increase as more sites are certified.
2. IRB: We will continue to add sites to Pearl IRB and develop reliance agreements.
3. Adjudication: The adjudication committee will continue reviewing new early discontinuation and potential infection cases with enrolled patients.
4. Site management: Administrative tasks associated with securing site participation will continue.
5. Screening and enrollment: Sites will begin screening and enrollment after completing the study training and certification process.
6. Data quality checks: Summary reports will be provided to the sites regularly. Data query reports will be sent out to sites to ensure data quality of the study.
7. Monthly check-in meetings: Monthly check-in calls to address any questions as the sites are implementing the study.
8. NCE request: The prime site (UMD) will send out extensions for all participating sites.

4. **IMPACT:** Describe distinctive contributions, major accomplishments, innovations, successes, or any change in practice or behavior that has come about as a result of the project relative to:

What was the impact on the development of the principal discipline(s) of the project?

If there is nothing significant to report during this reporting period, state “Nothing to Report.”

Describe how findings, results, techniques that were developed or extended, or other products from the project made an impact or are likely to make an impact on the base of knowledge, theory, and research in the principal disciplinary field(s) of the project. Summarize using language that an intelligent lay audience can understand (Scientific American style).

Nothing to report

What was the impact on other disciplines?

If there is nothing significant to report during this reporting period, state “Nothing to Report.”

Describe how the findings, results, or techniques that were developed or improved, or other products from the project made an impact or are likely to make an impact on other disciplines.

Nothing to report

What was the impact on technology transfer?

If there is nothing significant to report during this reporting period, state “Nothing to Report.”

Describe ways in which the project made an impact, or is likely to make an impact, on commercial technology or public use, including:

- *transfer of results to entities in government or industry;*
- *instances where the research has led to the initiation of a start-up company; or*
- *adoption of new practices.*

Nothing to report

What was the impact on society beyond science and technology?

If there is nothing significant to report during this reporting period, state “Nothing to Report.”

Describe how results from the project made an impact, or are likely to make an impact, beyond the bounds of science, engineering, and the academic world on areas such as:

- *improving public knowledge, attitudes, skills, and abilities;*
- *changing behavior, practices, decision making, policies (including regulatory policies), or social actions; or*
- *improving social, economic, civic, or environmental conditions.*

Nothing to Report

- 5. CHANGES/PROBLEMS:** *The PD/PI is reminded that the recipient organization is required to obtain prior written approval from the awarding agency grants official whenever there are significant changes in the project or its direction. If not previously reported in writing, provide the following additional information or state, "Nothing to Report," if applicable:*

Changes in approach and reasons for change

Describe any changes in approach during the reporting period and reasons for these changes. Remember that significant changes in objectives and scope require prior approval of the agency.

Nothing to report

Actual or anticipated problems or delays and actions or plans to resolve them

Describe problems or delays encountered during the reporting period and actions or plans to resolve them.

The delay caused by the new requirement for a single IRB is continuing to impact the certification timeline of the sites. Because the use of an sIRB is fairly new to most of our participating sites, it is slowing down both local and central IRB submission processes. We are providing extra time and effort for additional meetings and communications as our plan is to certify as many sites as possible before the next technical report.

As mentioned in the previous report, limited staff available to process the contracts and extensions at the University of Maryland (prime site) is causing a delay for the sites that require fully executed contracts or extensions prior to Pearl sIRB/HRPO submission or to begin screening/enrollment activity. The average time to process revisions can take at least 3 months at the prime site.

Due to a misunderstanding, the BSPH MCC never filed an application to become a pSite themselves, thinking that we were covered by the original single IRB application. The Tobra study was among the first METRC studies to require a single IRB, and for budgetary reasons, the PI chose to route this study through an external IRB, Pearl. In the original protocol application, the protocol clearly listed Renan Castillo as a co-investigator, and the BSPH MCC as the data coordinating center. The study was approved, and pSite applications were approved for the 35 sites where data collection activities will take place, and reliance agreements were executed for data collection. The requirement for a reliance agreement, the responsibility of which rests with the study PI, was not fully understood, and never clarified by any of the external IRB, our subcontracts office, or our sponsor. In terms of corrective action, we have applied and have an approval for reliance between BSPH IRB and Pearl IRB now. We are currently waiting to hear from BSPH IRB's response on this unanticipated event.

Changes that had a significant impact on expenditures

Describe changes during the reporting period that may have had a significant impact on expenditures, for example, delays in hiring staff or favorable developments that enable meeting objectives at less cost than anticipated.

Nothing to Report

Significant changes in use or care of human subjects, vertebrate animals, biohazards, and/or select agents

Describe significant deviations, unexpected outcomes, or changes in approved protocols for the use or care of human subjects, vertebrate animals, biohazards, and/or select agents during the reporting period. If required, were these changes approved by the applicable institution committee (or equivalent) and reported to the agency? Also specify the applicable Institutional Review Board/Institutional Animal Care and Use Committee approval dates.

Significant changes in use or care of human subjects

Nothing to Report

Significant changes in use or care of vertebrate animals

Nothing to Report

Significant changes in use of biohazards and/or select agents

Nothing to Report

6. PRODUCTS: *List any products resulting from the project during the reporting period. If there is nothing to report under a particular item, state "Nothing to Report."*

- Publications, conference papers, and presentations**

Report only the major publication(s) resulting from the work under this award.

Journal publications. *List peer-reviewed articles or papers appearing in scientific, technical, or professional journals. Identify for each publication: Author(s); title; journal; volume; year; page numbers; status of publication (published; accepted, awaiting publication; submitted, under review; other); acknowledgement of federal support (yes/no).*

Nothing to Report

Books or other non-periodical, one-time publications. *Report any book, monograph, dissertation, abstract, or the like published as or in a separate publication, rather than a periodical or series. Include any significant publication in the proceedings of a one-time*

conference or in the report of a one-time study, commission, or the like. Identify for each one-time publication: author(s); title; editor; title of collection, if applicable; bibliographic information; year; type of publication (e.g., book, thesis or dissertation); status of publication (published; accepted, awaiting publication; submitted, under review; other); acknowledgement of federal support (yes/no).

Nothing to Report

Other publications, conference papers and presentations. *Identify any other publications, conference papers and/or presentations not reported above. Specify the status of the publication as noted above. List presentations made during the last year (international, national, local societies, military meetings, etc.). Use an asterisk (*) if presentation produced a manuscript.*

Nothing to Report

- **Website(s) or other Internet site(s)**

List the URL for any Internet site(s) that disseminates the results of the research activities. A short description of each site should be provided. It is not necessary to include the publications already specified above in this section.

Nothing to Report

- **Technologies or techniques**

Identify technologies or techniques that resulted from the research activities. Describe the technologies or techniques were shared.

Nothing to Report

- **Inventions, patent applications, and/or licenses**

Identify inventions, patent applications with date, and/or licenses that have resulted from the research. Submission of this information as part of an interim research performance progress report is not a substitute for any other invention reporting required under the terms and conditions of an award.

Nothing to Report

- **Other Products**

Identify any other reportable outcomes that were developed under this project. Reportable outcomes are defined as a research result that is or relates to a product, scientific advance, or research tool that makes a meaningful contribution toward the understanding, prevention,

diagnosis, prognosis, treatment and /or rehabilitation of a disease, injury or condition, or to improve the quality of life. Examples include:

- *data or databases;*
- *physical collections;*
- *audio or video products;*
- *software;*
- *models;*
- *educational aids or curricula;*
- *instruments or equipment;*
- *research material (e.g., Germplasm; cell lines, DNA probes, animal models);*
- *clinical interventions;*
- *new business creation; and*
- *other.*

Nothing to Report

7. PARTICIPANTS & OTHER COLLABORATING ORGANIZATIONS

What individuals have worked on the project?

Provide the following information for: (1) PDs/PIs; and (2) each person who has worked at least one person month per year on the project during the reporting period, regardless of the source of compensation (a person month equals approximately 160 hours of effort). If information is unchanged from a previous submission, provide the name only and indicate “no change”.

Example:

Name: Mary Smith

Project Role: Graduate Student

Researcher Identifier (e.g. ORCID ID): 1234567

Nearest person month worked: 5

Contribution to Project: Ms. Smith has performed work in the area of combined error-control and constrained coding.

Funding Support: The Ford Foundation (Complete only if the funding support is provided from other than this award.)

Name:	Robert O'Toole
Project Role:	Principal Investigator
ORCID ID:	0000-0002-5628-6584
Effort:	10%
Contribution:	Dr. O'Toole led the overall project effort and has overseen the development of the study protocol and submission of the IND application to the FDA.
Name:	Manjari Joshi
Project Role:	Co-Investigator

ORCID ID:	Not available
Effort:	5%
Contribution:	Dr. Joshi has provided oversight and expertise on all project matters related to infectious disease.
Name:	Nathan O'Hara
Project Role:	Co-Investigator
ORCID ID:	0000-0003-0537-3474
Effort:	15%
Contribution:	Mr. O'Hara has managed all administrative aspects of the project at the lead institution and contributed to the development of the protocol.
Name:	Renan Castillo
Project Role:	MCC Principal Investigator
ORCID ID:	0000-0003-0473-5891
Effort:	15%
Contribution:	Dr. Castillo contributed to the development of protocol and statistical planning as well as led all project efforts at the METRC Coordinating Center.
Name:	Anthony Carlini
Project Role:	MCC Co-Investigator
ORCID ID:	0000-0003-1419-4515
Effort:	15%
Contribution:	Mr. Carlini has organized all project efforts across institutions and has developed/drafted study documents and reports.
Name:	Suna Chung
Project Role:	MCC Project Director
ORCID ID:	Not Available
Effort:	30%
Contribution:	Ms. Chung has organized all project efforts across institutions and has developed/drafted study documents and reports.
Name:	Richard Thompson
Project Role:	Biostatistician
ORCID ID:	0000-0001-8378-4426
Effort:	15%
Contribution:	Dr. Thompson has oversight and expertise on all project matters related to statistical planning.
Name:	Susan Collins
Project Role:	Study Manager
ORCID ID:	Not Available
Effort:	60%
Contribution:	Ms. Collins corresponded with participating centers, organized site survey responses, and drafted the consent documents and case report forms.
Name:	Elias Weston-Farber
Project Role:	Programmer
ORCID ID:	Not Available
Effort:	30%
Contribution:	

	Mr. Weston-Farber supports the analysis of the data under the supervision of the study investigators.
Name: Project Role: ORCID ID: Effort: Contribution:	Paige Sullivan Programmer Not Available 30% Ms. Sullivan supports programming of the REDCap database under the supervision of the study investigators.
Name: Project Role: ORCID ID: Effort: Contribution:	Jack Dagg Data Analyst Not Available 45% Mr. Dagg supports the analysis of the data under the supervision of the study investigators.
Name: Project Role: ORCID ID: Effort: Contribution:	Chris Witczak Financial Analyst Not Available 6% Mr. Witczak set up the study account and prepared subaward paperwork for participating centers.

Has there been a change in the active other support of the PD/PI(s) or senior/key personnel since the last reporting period?

If there is nothing significant to report during this reporting period, state “Nothing to Report.”

If the active support has changed for the PD/PI(s) or senior/key personnel, then describe what the change has been. Changes may occur, for example, if a previously active grant has closed and/or if a previously pending grant is now active. Annotate this information so it is clear what has changed from the previous submission. Submission of other support information is not necessary for pending changes or for changes in the level of effort for active support reported previously. The awarding agency may require prior written approval if a change in active other support significantly impacts the effort on the project that is the subject of the project report.

Nothing to Report

What other organizations were involved as partners?

If there is nothing significant to report during this reporting period, state “Nothing to Report.”

Describe partner organizations – academic institutions, other nonprofits, industrial or commercial firms, state or local governments, schools or school systems, or other organizations (foreign or domestic) – that were involved with the project. Partner organizations may have provided financial or in-kind support, supplied facilities or equipment, collaborated in the research, exchanged personnel, or otherwise contributed.

Provide the following information for each partnership:

Organization Name:

Location of Organization: (if foreign location list country)

Partner's contribution to the project (identify one or more)

- *Financial support;*
- *In-kind support (e.g., partner makes software, computers, equipment, etc., available to project staff);*
- *Facilities (e.g., project staff use the partner's facilities for project activities);*
- *Collaboration (e.g., partner's staff work with project staff on the project);*
- *Personnel exchanges (e.g., project staff and/or partner's staff use each other's facilities, work at each other's site); and*

Nothing to Report

8. SPECIAL REPORTING REQUIREMENTS

COLLABORATIVE AWARDS: *For collaborative awards, independent reports are required from BOTH the Initiating Principal Investigator (PI) and the Collaborating/Partnering PI. A duplicative report is acceptable; however, tasks shall be clearly marked with the responsible PI and research site. A report shall be submitted to <https://ers.amedd.army.mil> for each unique award.*

QUAD CHARTS: *If applicable, the Quad Chart (available on <https://www.usamraa.army.mil>) should be updated and submitted with attachments.*

An updated Quad Chart is included as Attachment 1.

- 9. APPENDICES:** *Attach all appendices that contain information that supplements, clarifies or supports the text. Examples include original copies of journal articles, reprints of manuscripts and abstracts, a curriculum vitae, patent applications, study questionnaires, and surveys, etc.*

Please see page 16 for the summary report.

TABLE 1a: Screening, Eligibility, and Enrollment by Site

Clinical Site	Last 14 Days			Average per week		Cumulative, to date							
	Screened	Eligible	Enrolled	Screened	Enrolled	Screened	Eligible (% screened)	Refused (% eligible)	Non-enrolled for 'other' reasons (% eligible)	Discontinued, pre-enrollment (% eligible)	Consented & Randomized (% eligible)	Discontinued, pre-r0 (% randomized)	Eligible & Enrolled (% randomized)
CAP	0	0	0	1.46	0.45	141	51 (36%)	4 (8%)	2 (4%)	0 (0%)	45 (88%)	2 (4%)	43 (96%)
CED	0	0	0	0.14	0.14	4	4 (100%)	0 (0%)	0 (0%)	0 (0%)	4 (100%)	0 (0%)	4 (100%)
CMC	9	7	3	3.13	0.51	253	92 (36%)	36 (39%)	9 (10%)	0 (0%)	47 (51%)	6 (13%)	41 (87%)
DAR	2	2	2	0.52	0.38	34	29 (85%)	1 (3%)	0 (0%)	0 (0%)	28 (97%)	3 (11%)	25 (89%)
HCM	1	1	1	0.15	0.12	12	10 (83%)	0 (0%)	1 (10%)	0 (0%)	9 (90%)	0 (0%)	9 (100%)
HOU	0	0	0	1.97	0.82	167	134 (80%)	23 (17%)	35 (26%)	0 (0%)	76 (57%)	6 (8%)	70 (92%)
HRV	0	0	0	0.55	0.36	38	35 (92%)	2 (6%)	8 (23%)	0 (0%)	25 (71%)	0 (0%)	25 (100%)
IFH	3	2	2	0.91	0.38	83	60 (72%)	11 (18%)	13 (22%)	1 (2%)	35 (58%)	0 (0%)	35 (100%)
LOY	3	3	2	0.72	0.26	11	5 (45%)	1 (20%)	0 (0%)	0 (0%)	4 (80%)	0 (0%)	4 (100%)
LUB	1	1	1	0.4	0.37	12	12 (100%)	0 (0%)	1 (8%)	0 (0%)	11 (92%)	0 (0%)	11 (100%)
MET	0	0	0	1.17	0.23	99	31 (31%)	7 (23%)	5 (16%)	0 (0%)	19 (61%)	0 (0%)	19 (100%)
MTH	5	2	1	2.78	0.53	233	69 (30%)	2 (3%)	16 (23%)	2 (3%)	49 (71%)	5 (10%)	44 (90%)
OSU	0	0	0	0.25	0.09	11	4 (36%)	0 (0%)	0 (0%)	0 (0%)	4 (100%)	0 (0%)	4 (100%)
PSU	2	2	1	0.73	0.15	5	4 (80%)	2 (50%)	0 (0%)	0 (0%)	2 (50%)	1 (50%)	1 (50%)
RIH	1	1	1	0.64	0.1	45	13 (29%)	2 (15%)	3 (23%)	0 (0%)	8 (62%)	1 (13%)	7 (88%)
SAN	2	2	1	0.78	0.29	24	12 (50%)	0 (0%)	3 (25%)	0 (0%)	9 (75%)	0 (0%)	9 (100%)
SHS	1	1	1	0.5	0.39	41	39 (95%)	6 (15%)	0 (0%)	0 (0%)	33 (85%)	1 (3%)	32 (97%)
UAB	3	3	3	0.88	0.81	35	35 (100%)	0 (0%)	0 (0%)	0 (0%)	35 (100%)	3 (9%)	32 (91%)
UCH	0	0	0	0.2	0.2	15	15 (100%)	0 (0%)	0 (0%)	0 (0%)	15 (100%)	0 (0%)	15 (100%)
UKY	2	2	2	1.01	0.98	30	30 (100%)	0 (0%)	0 (0%)	0 (0%)	30 (100%)	1 (3%)	29 (97%)
UMD	5	4	4	2.52	0.99	305	153 (50%)	18 (12%)	10 (7%)	0 (0%)	125 (82%)	5 (4%)	120 (96%)
UMS	3	3	2	1.6	0.67	121	85 (70%)	13 (15%)	19 (22%)	0 (0%)	53 (62%)	2 (4%)	51 (96%)
UOK	2	2	2	0.9	0.5	69	44 (64%)	2 (5%)	2 (5%)	0 (0%)	40 (91%)	2 (5%)	38 (95%)
USC	1	1	1	0.66	0.41	34	26 (76%)	4 (15%)	1 (4%)	0 (0%)	21 (81%)	0 (0%)	21 (100%)
UVA	0	0	0	0.4	0.17	28	18 (64%)	5 (28%)	1 (6%)	0 (0%)	12 (67%)	0 (0%)	12 (100%)
UWI	1	1	1	1.4	0.35	133	42 (32%)	4 (10%)	5 (12%)	0 (0%)	33 (79%)	0 (0%)	33 (100%)
VCU	0	0	0	0.88	0	2	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
VMC	4	3	3	1.33	0.74	93	68 (73%)	8 (12%)	8 (12%)	0 (0%)	52 (76%)	0 (0%)	52 (100%)
WFU	4	0	0	2.12	0.3	156	33 (21%)	5 (15%)	4 (12%)	0 (0%)	24 (73%)	2 (8%)	22 (92%)
TOTAL	55	43	34	.	.	2235	1153 (52%)	156 (14%)	146 (13%)	3 (0%)	848 (74%)	40 (5%)	808 (95%)

TABLE 2a: Reasons for Ineligibility by Site

Clinical Site	Screened, to date	Ineligible, to date (% screened)	Ineligibility Reason (% screened)								
			Failed Fracture criteria	Failed age criteria	Prior/ current deep SSL	Already received definitive fixation	Myonecrosis	Pregnant or lactating	Follow-up concerns	Vanco allergies	Tobra/ aminoglycoside allergies
CAP	141	90 (64%)	59 (42%)	8 (6%)	1 (1%)	8 (6%)	0 (0%)	0 (0%)	26 (18%)	0 (0%)	0 (0%)
CED	4	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
CMC	253	161 (64%)	147 (58%)	5 (2%)	0 (0%)	7 (3%)	0 (0%)	1 (0%)	4 (2%)	1 (0%)	0 (0%)
DAR	34	5 (15%)	5 (15%)	1 (3%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
HCM	12	2 (17%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	2 (17%)	0 (0%)	0 (0%)
HOU	167	33 (20%)	0 (0%)	1 (1%)	1 (1%)	14 (8%)	0 (0%)	2 (1%)	15 (9%)	0 (0%)	0 (0%)
HRV	38	3 (8%)	0 (0%)	1 (3%)	0 (0%)	1 (3%)	0 (0%)	0 (0%)	0 (0%)	1 (3%)	0 (0%)
IFH	83	23 (28%)	0 (0%)	0 (0%)	1 (1%)	1 (1%)	0 (0%)	0 (0%)	20 (24%)	1 (1%)	1 (1%)
LOY	11	6 (55%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	6 (55%)	0 (0%)	0 (0%)
LUB	12	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
MET	99	68 (69%)	21 (21%)	1 (1%)	0 (0%)	16 (16%)	0 (0%)	1 (1%)	33 (33%)	1 (1%)	1 (1%)
MTH	233	164 (70%)	98 (42%)	2 (1%)	1 (0%)	32 (14%)	0 (0%)	0 (0%)	38 (16%)	1 (0%)	0 (0%)
OSU	11	7 (64%)	5 (45%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	2 (18%)	0 (0%)	0 (0%)
PSU	5	1 (20%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (20%)	0 (0%)	0 (0%)	0 (0%)
RIH	45	32 (71%)	5 (11%)	3 (7%)	0 (0%)	20 (44%)	0 (0%)	0 (0%)	4 (9%)	0 (0%)	0 (0%)
SAN	24	12 (50%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	12 (50%)	0 (0%)	0 (0%)
SHS	41	2 (5%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	2 (5%)	0 (0%)	0 (0%)
UAB	35	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
UCH	15	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
UKY	30	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
UMD	305	152 (50%)	129 (42%)	1 (0%)	1 (0%)	2 (1%)	0 (0%)	2 (1%)	17 (6%)	1 (0%)	0 (0%)
UMS	121	36 (30%)	2 (2%)	0 (0%)	4 (3%)	18 (15%)	0 (0%)	0 (0%)	18 (15%)	0 (0%)	0 (0%)
UOK	69	25 (36%)	0 (0%)	1 (1%)	4 (6%)	20 (29%)	2 (3%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)
USC	34	8 (24%)	3 (9%)	1 (3%)	0 (0%)	2 (6%)	0 (0%)	0 (0%)	2 (6%)	0 (0%)	0 (0%)
UVA	28	10 (36%)	3 (11%)	0 (0%)	0 (0%)	2 (7%)	0 (0%)	0 (0%)	4 (14%)	0 (0%)	0 (0%)
UWI	133	91 (68%)	78 (59%)	2 (2%)	0 (0%)	3 (2%)	0 (0%)	0 (0%)	11 (8%)	0 (0%)	0 (0%)
VCU	2	2 (100%)	1 (50%)	0 (0%)	0 (0%)	1 (50%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
VMC	93	25 (27%)	8 (9%)	4 (4%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	11 (12%)	1 (1%)	0 (0%)
WFO	156	123 (79%)	74 (47%)	2 (1%)	0 (0%)	29 (19%)	0 (0%)	0 (0%)	22 (14%)	2 (1%)	0 (0%)
TOTAL	2235	1082 (48%)	638 (29%)	33 (1%)	13 (1%)	177 (8%)	2 (0%)	7 (0%)	250 (11%)	9 (0%)	2 (0%)

TABLE 5a: Week 2 Follow-up Status by Site

Clinical site	Eligible & Enrolled	DF complete	Due	Week 2 CRF09 (Patient Reported) Status							Week 2 CRF08 (Medical Record Review) Status						
				Complete (% due)	Incomplete (% due)	Not Started, <30 days (% due)	Not Started, >30 days (% due)	Missed (% due)	Early (% complete)	Late (% complete)	Complete (% due)	Incomplete (% due)	Not Started, <30 days (% due)	Not Started, >30 days (% due)	Missed (% due)	Early (% complete)	Late (% complete)
CAP	43	41	41	40 (98%)	0 (0%)	0 (0%)	1 (2%)	0 (0%)	3 (8%)	0 (0%)	40 (98%)	0 (0%)	0 (0%)	1 (2%)	0 (0%)	3 (8%)	0 (0%)
CED	4	4	4	4 (100%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	4 (100%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
CMC	41	37	36	34 (94%)	0 (0%)	1 (3%)	1 (3%)	0 (0%)	6 (18%)	1 (3%)	34 (94%)	0 (0%)	1 (3%)	1 (3%)	0 (0%)	6 (18%)	0 (0%)
DAR	25	23	23	21 (91%)	0 (0%)	2 (9%)	0 (0%)	0 (0%)	1 (5%)	0 (0%)	21 (91%)	0 (0%)	2 (9%)	0 (0%)	0 (0%)	1 (5%)	0 (0%)
HCM	9	7	7	6 (86%)	0 (0%)	0 (0%)	0 (0%)	1 (14%)	2 (33%)	0 (0%)	6 (86%)	0 (0%)	0 (0%)	0 (0%)	1 (14%)	2 (33%)	0 (0%)
HOU	70	67	67	65 (97%)	0 (0%)	1 (1%)	1 (1%)	0 (0%)	5 (8%)	0 (0%)	65 (97%)	0 (0%)	1 (1%)	1 (1%)	0 (0%)	5 (8%)	0 (0%)
HRV	25	3	3	2 (67%)	0 (0%)	0 (0%)	0 (0%)	1 (33%)	0 (0%)	0 (0%)	2 (67%)	0 (0%)	0 (0%)	0 (0%)	1 (33%)	0 (0%)	0 (0%)
IFH	35	33	32	32 (100%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	2 (6%)	0 (0%)	32 (100%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	2 (6%)	0 (0%)
LOY	4	3	2	0 (0%)	0 (0%)	2 (100%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	2 (100%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
LUB	11	0	0	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
MET	19	18	18	18 (100%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (6%)	0 (0%)	18 (100%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	2 (11%)	0 (0%)
MTH	44	44	43	41 (95%)	0 (0%)	2 (5%)	0 (0%)	0 (0%)	2 (5%)	0 (0%)	41 (95%)	0 (0%)	2 (5%)	0 (0%)	0 (0%)	2 (5%)	0 (0%)
OSU	4	2	2	2 (100%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	2 (100%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
PSU	1	1	1	0 (0%)	0 (0%)	1 (100%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (100%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
RIH	7	6	6	5 (83%)	0 (0%)	1 (17%)	0 (0%)	0 (0%)	1 (20%)	0 (0%)	5 (83%)	0 (0%)	1 (17%)	0 (0%)	0 (0%)	1 (20%)	0 (0%)
SAN	9	9	8	5 (63%)	0 (0%)	2 (25%)	1 (13%)	0 (0%)	1 (20%)	0 (0%)	5 (63%)	0 (0%)	2 (25%)	1 (13%)	0 (0%)	1 (20%)	0 (0%)
SHS	32	31	31	30 (97%)	0 (0%)	1 (3%)	0 (0%)	0 (0%)	2 (7%)	0 (0%)	30 (97%)	0 (0%)	1 (3%)	0 (0%)	0 (0%)	2 (7%)	0 (0%)
UAB	32	27	25	24 (96%)	0 (0%)	1 (4%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	24 (96%)	0 (0%)	1 (4%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
UCH	15	15	15	15 (100%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	3 (20%)	0 (0%)	15 (100%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	2 (13%)	0 (0%)
UKY	29	27	25	23 (92%)	0 (0%)	1 (4%)	1 (4%)	0 (0%)	1 (4%)	0 (0%)	23 (92%)	0 (0%)	1 (4%)	1 (4%)	0 (0%)	1 (4%)	0 (0%)
UMD	120	116	112	109 (97%)	1 (1%)	1 (1%)	0 (0%)	1 (1%)	1 (1%)	0 (0%)	109 (97%)	0 (0%)	2 (2%)	0 (0%)	1 (1%)	1 (1%)	0 (0%)
UMS	51	48	48	45 (94%)	0 (0%)	2 (4%)	1 (2%)	0 (0%)	2 (4%)	0 (0%)	45 (94%)	0 (0%)	2 (4%)	1 (2%)	0 (0%)	1 (2%)	0 (0%)
UOK	38	26	26	20 (77%)	0 (0%)	0 (0%)	2 (8%)	4 (15%)	5 (25%)	0 (0%)	20 (77%)	0 (0%)	0 (0%)	2 (8%)	4 (15%)	5 (25%)	0 (0%)
USC	21	18	18	15 (83%)	0 (0%)	1 (6%)	1 (6%)	1 (6%)	0 (0%)	0 (0%)	15 (83%)	0 (0%)	1 (6%)	1 (6%)	1 (6%)	0 (0%)	0 (0%)
UVA	12	8	8	7 (88%)	0 (0%)	0 (0%)	0 (0%)	1 (13%)	2 (29%)	0 (0%)	6 (75%)	0 (0%)	0 (0%)	0 (0%)	2 (25%)	2 (33%)	0 (0%)
UWI	33	31	30	30 (100%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	3 (10%)	0 (0%)	30 (100%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	2 (7%)	0 (0%)
VMC	52	47	45	41 (91%)	0 (0%)	1 (2%)	1 (2%)	2 (4%)	5 (12%)	0 (0%)	41 (91%)	0 (0%)	1 (2%)	1 (2%)	2 (4%)	5 (12%)	0 (0%)
WFU	22	22	22	22 (100%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	21 (95%)	1 (5%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
TOTAL	808	714	698	656 (94%)	1 (0%)	20 (3%)	10 (1%)	11 (2%)	48 (7%)	1 (0%)	654 (94%)	1 (0%)	21 (3%)	10 (1%)	12 (2%)	46 (7%)	0 (0%)

TABLE 6a: Month 3 Follow-up Status by Site

Clinical site	Eligible & Enrolled	DF complete	Due	Month 3 CRF09 (Patient Reported) Status							Month 3 CRF08 (Medical Record Review) Status						
				Complete (% due)	Incomplete (% due)	Not Started, <=30 days (% due)	Not Started, >30 days (% due)	Missed (% due)	Early (% complete)	Late (% complete)	Complete (% due)	Incomplete (% due)	Not Started, <=30 days (% due)	Not Started, >30 days (% due)	Missed (% due)	Early (% complete)	Late (% complete)
CAP	43	41	36	31 (86%)	1 (3%)	0 (0%)	4 (11%)	0 (0%)	9 (29%)	0 (0%)	32 (89%)	0 (0%)	0 (0%)	4 (11%)	0 (0%)	9 (28%)	0 (0%)
CED	4	4	3	2 (67%)	0 (0%)	0 (0%)	1 (33%)	0 (0%)	1 (50%)	0 (0%)	2 (67%)	0 (0%)	0 (0%)	1 (33%)	0 (0%)	1 (50%)	0 (0%)
CMC	41	37	30	24 (80%)	5 (17%)	0 (0%)	1 (3%)	0 (0%)	10 (42%)	0 (0%)	29 (97%)	0 (0%)	0 (0%)	1 (3%)	0 (0%)	11 (38%)	0 (0%)
DAR	25	23	17	15 (88%)	0 (0%)	0 (0%)	1 (6%)	1 (6%)	7 (47%)	0 (0%)	15 (88%)	0 (0%)	0 (0%)	1 (6%)	1 (6%)	7 (47%)	0 (0%)
HCM	9	7	7	6 (86%)	0 (0%)	0 (0%)	1 (14%)	0 (0%)	4 (67%)	0 (0%)	6 (86%)	0 (0%)	0 (0%)	1 (14%)	0 (0%)	4 (67%)	0 (0%)
HOU	70	67	59	39 (66%)	6 (10%)	4 (7%)	2 (3%)	8 (14%)	5 (13%)	1 (3%)	45 (76%)	0 (0%)	4 (7%)	2 (3%)	8 (14%)	6 (13%)	1 (2%)
HRV	25	3	3	0 (0%)	0 (0%)	0 (0%)	0 (0%)	3 (100%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	3 (100%)	0 (0%)	0 (0%)
IFH	35	33	24	23 (96%)	1 (4%)	0 (0%)	0 (0%)	0 (0%)	1 (4%)	0 (0%)	23 (96%)	1 (4%)	0 (0%)	0 (0%)	0 (0%)	1 (4%)	0 (0%)
LOY	4	3	0	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
LUB	11	0	0	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
MET	19	18	18	16 (89%)	1 (6%)	1 (6%)	0 (0%)	0 (0%)	4 (25%)	0 (0%)	17 (94%)	0 (0%)	1 (6%)	0 (0%)	0 (0%)	4 (25%)	0 (0%)
MTH	44	44	36	34 (94%)	0 (0%)	0 (0%)	1 (3%)	1 (3%)	3 (9%)	0 (0%)	34 (94%)	0 (0%)	0 (0%)	1 (3%)	1 (3%)	3 (9%)	0 (0%)
OSU	4	2	2	0 (0%)	0 (0%)	0 (0%)	2 (100%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	2 (100%)	0 (0%)	0 (0%)	0 (0%)
PSU	1	1	0	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
RIH	7	6	4	3 (75%)	0 (0%)	1 (25%)	0 (0%)	0 (0%)	1 (33%)	0 (0%)	4 (100%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
SAN	9	9	4	4 (100%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	4 (100%)	0 (0%)	4 (100%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	4 (100%)	0 (0%)
SHS	32	31	21	20 (95%)	1 (5%)	0 (0%)	0 (0%)	0 (0%)	5 (25%)	1 (5%)	20 (95%)	1 (5%)	0 (0%)	0 (0%)	0 (0%)	4 (20%)	1 (5%)
UAB	32	27	18	9 (50%)	7 (39%)	0 (0%)	0 (0%)	2 (11%)	1 (11%)	0 (0%)	16 (89%)	0 (0%)	0 (0%)	0 (0%)	2 (11%)	4 (25%)	0 (0%)
UCH	15	15	13	13 (100%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	2 (15%)	0 (0%)	13 (100%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	2 (15%)	0 (0%)
UKY	29	27	18	10 (56%)	0 (0%)	1 (6%)	4 (22%)	3 (17%)	6 (60%)	0 (0%)	10 (56%)	1 (6%)	1 (6%)	4 (22%)	2 (11%)	6 (60%)	0 (0%)
UMD	120	116	94	91 (97%)	0 (0%)	0 (0%)	0 (0%)	3 (3%)	3 (3%)	0 (0%)	91 (97%)	0 (0%)	0 (0%)	0 (0%)	3 (3%)	3 (3%)	0 (0%)
UMS	51	48	42	33 (79%)	0 (0%)	1 (2%)	1 (2%)	7 (17%)	8 (24%)	1 (3%)	33 (79%)	0 (0%)	1 (2%)	1 (2%)	7 (17%)	7 (21%)	2 (6%)
UOK	38	26	24	4 (17%)	12 (50%)	0 (0%)	1 (4%)	7 (29%)	4 (100%)	0 (0%)	12 (50%)	4 (17%)	0 (0%)	1 (4%)	7 (29%)	7 (58%)	0 (0%)
USC	21	18	16	10 (63%)	0 (0%)	1 (6%)	3 (19%)	2 (13%)	0 (0%)	0 (0%)	10 (63%)	0 (0%)	1 (6%)	3 (19%)	2 (13%)	0 (0%)	0 (0%)
UVA	12	8	8	2 (25%)	2 (25%)	0 (0%)	2 (25%)	2 (25%)	2 (100%)	0 (0%)	3 (38%)	0 (0%)	0 (0%)	3 (38%)	2 (25%)	2 (67%)	0 (0%)
UWI	33	31	23	20 (87%)	0 (0%)	2 (9%)	1 (4%)	0 (0%)	3 (15%)	0 (0%)	20 (87%)	1 (4%)	1 (4%)	1 (4%)	0 (0%)	3 (15%)	0 (0%)
VMC	52	47	38	32 (84%)	1 (3%)	0 (0%)	0 (0%)	5 (13%)	20 (63%)	0 (0%)	33 (87%)	0 (0%)	0 (0%)	0 (0%)	5 (13%)	21 (64%)	0 (0%)
WFU	22	22	19	13 (68%)	0 (0%)	0 (0%)	2 (11%)	4 (21%)	2 (15%)	0 (0%)	13 (68%)	0 (0%)	0 (0%)	2 (11%)	4 (21%)	2 (15%)	0 (0%)
TOTAL	808	714	577	454 (79%)	37 (6%)	11 (2%)	27 (5%)	48 (8%)	105 (23%)	3 (1%)	485 (84%)	8 (1%)	9 (2%)	28 (5%)	47 (8%)	111 (23%)	4 (1%)

TABLE 7a: Month 6 Follow-up Status by Site

Clinical site	Eligible & Enrolled	DF complete	Due	Month 6 CRF09 (Patient Reported) Status							Month 6 CRF08 (Medical Record Review) Status						
				Complete (% due)	Incomplete (% due)	Not Started, <=30 days (% due)	Not Started, >30 days (% due)	Missed (% due)	Early (% complete)	Late (% complete)	Complete (% due)	Incomplete (% due)	Not Started, <=30 days (% due)	Not Started, >30 days (% due)	Missed (% due)	Early (% complete)	Late (% complete)
CAP	43	41	28	24 (86%)	1 (4%)	0 (0%)	2 (7%)	1 (4%)	4 (17%)	0 (0%)	25 (89%)	0 (0%)	0 (0%)	2 (7%)	1 (4%)	4 (16%)	0 (0%)
CED	4	4	1	0 (0%)	0 (0%)	1 (100%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (100%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
CMC	41	37	24	16 (67%)	4 (17%)	0 (0%)	3 (13%)	1 (4%)	6 (38%)	0 (0%)	18 (75%)	2 (8%)	0 (0%)	3 (13%)	1 (4%)	5 (28%)	0 (0%)
DAR	25	23	13	10 (77%)	0 (0%)	0 (0%)	1 (8%)	2 (15%)	4 (40%)	0 (0%)	10 (77%)	0 (0%)	0 (0%)	1 (8%)	2 (15%)	4 (40%)	0 (0%)
HCM	9	7	6	5 (83%)	0 (0%)	0 (0%)	0 (0%)	1 (17%)	1 (20%)	0 (0%)	5 (83%)	0 (0%)	0 (0%)	0 (0%)	1 (17%)	1 (20%)	0 (0%)
HOU	70	67	49	25 (51%)	3 (6%)	4 (8%)	10 (20%)	7 (14%)	3 (12%)	1 (4%)	28 (57%)	0 (0%)	4 (8%)	10 (20%)	7 (14%)	3 (11%)	1 (4%)
HRV	25	3	3	0 (0%)	0 (0%)	0 (0%)	0 (0%)	3 (100%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	3 (100%)	0 (0%)	0 (0%)
IFH	35	33	22	18 (82%)	0 (0%)	1 (5%)	3 (14%)	0 (0%)	0 (0%)	0 (0%)	17 (77%)	1 (5%)	1 (5%)	3 (14%)	0 (0%)	0 (0%)	0 (0%)
LOY	4	3	0	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
LUB	11	0	0	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
MET	19	18	16	14 (88%)	0 (0%)	1 (6%)	1 (6%)	0 (0%)	2 (14%)	0 (0%)	14 (88%)	0 (0%)	1 (6%)	1 (6%)	0 (0%)	2 (14%)	0 (0%)
MTH	44	44	29	24 (83%)	0 (0%)	2 (7%)	1 (3%)	2 (7%)	2 (8%)	0 (0%)	24 (83%)	0 (0%)	2 (7%)	1 (3%)	2 (7%)	2 (8%)	0 (0%)
OSU	4	2	0	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
PSU	1	1	0	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
RIH	7	6	2	2 (100%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (50%)	0 (0%)	2 (100%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (50%)	0 (0%)
SAN	9	9	1	1 (100%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (100%)	0 (0%)	1 (100%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (100%)	0 (0%)
SHS	32	31	20	15 (75%)	2 (10%)	1 (5%)	2 (10%)	0 (0%)	1 (7%)	0 (0%)	15 (75%)	2 (10%)	1 (5%)	2 (10%)	0 (0%)	1 (7%)	0 (0%)
UAB	32	27	13	0 (0%)	4 (31%)	4 (31%)	5 (38%)	0 (0%)	0 (0%)	0 (0%)	4 (31%)	0 (0%)	4 (31%)	5 (38%)	0 (0%)	0 (0%)	0 (0%)
UCH	15	15	8	6 (75%)	0 (0%)	2 (25%)	0 (0%)	0 (0%)	2 (33%)	0 (0%)	6 (75%)	0 (0%)	2 (25%)	0 (0%)	0 (0%)	2 (33%)	0 (0%)
UKY	29	27	8	2 (25%)	0 (0%)	6 (75%)	0 (0%)	0 (0%)	1 (50%)	0 (0%)	2 (25%)	0 (0%)	6 (75%)	0 (0%)	0 (0%)	1 (50%)	0 (0%)
UMD	120	116	83	76 (92%)	0 (0%)	1 (1%)	2 (2%)	4 (5%)	3 (4%)	0 (0%)	76 (92%)	0 (0%)	1 (1%)	2 (2%)	4 (5%)	3 (4%)	0 (0%)
UMS	51	48	37	12 (32%)	2 (5%)	2 (5%)	11 (30%)	10 (27%)	3 (25%)	0 (0%)	14 (38%)	0 (0%)	2 (5%)	11 (30%)	10 (27%)	3 (21%)	0 (0%)
UOK	38	26	23	1 (4%)	11 (48%)	1 (4%)	3 (13%)	7 (30%)	1 (100%)	0 (0%)	7 (30%)	5 (22%)	1 (4%)	3 (13%)	7 (30%)	5 (71%)	0 (0%)
USC	21	18	12	7 (58%)	0 (0%)	2 (17%)	3 (25%)	0 (0%)	0 (0%)	0 (0%)	7 (58%)	0 (0%)	2 (17%)	3 (25%)	0 (0%)	0 (0%)	0 (0%)
UVA	12	8	5	3 (60%)	1 (20%)	0 (0%)	1 (20%)	0 (0%)	1 (33%)	0 (0%)	4 (80%)	0 (0%)	0 (0%)	1 (20%)	0 (0%)	1 (25%)	0 (0%)
UWI	33	31	18	17 (94%)	0 (0%)	0 (0%)	0 (0%)	1 (6%)	2 (12%)	0 (0%)	17 (94%)	0 (0%)	0 (0%)	0 (0%)	1 (6%)	2 (12%)	0 (0%)
VMC	52	47	26	18 (69%)	0 (0%)	1 (4%)	2 (8%)	5 (19%)	9 (50%)	0 (0%)	18 (69%)	0 (0%)	1 (4%)	2 (8%)	5 (19%)	9 (50%)	0 (0%)
WFU	22	22	13	8 (62%)	0 (0%)	1 (8%)	3 (23%)	1 (8%)	1 (13%)	0 (0%)	8 (62%)	0 (0%)	1 (8%)	3 (23%)	1 (8%)	1 (13%)	0 (0%)
TOTAL	808	714	460	304 (66%)	28 (6%)	30 (7%)	53 (12%)	45 (10%)	48 (16%)	1 (0%)	322 (70%)	10 (2%)	30 (7%)	53 (12%)	45 (10%)	51 (16%)	1 (0%)

TABLE 8a: Month 12 Follow-up Status by Site

Clinical site	Eligible & Enrolled	DF complete	Due	Month 12 CRF09 (Patient Reported) Status							Month 12 CRF08 (Medical Record Review) Status						
				Complete (% due)	Incomplete (% due)	Not Started, <=30 days (% due)	Not Started, >30 days (% due)	Missed (% due)	Early (% complete)	Late (% complete)	Complete (% due)	Incomplete (% due)	Not Started, <=30 days (% due)	Not Started, >30 days (% due)	Missed (% due)	Early (% complete)	Late (% complete)
CAP	43	41	19	14 (74%)	0 (0%)	3 (16%)	2 (11%)	0 (0%)	0 (0%)	0 (0%)	15 (79%)	0 (0%)	3 (16%)	1 (5%)	0 (0%)	0 (0%)	0 (0%)
CED	4	4	0	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)
CMC	41	37	16	9 (56%)	2 (13%)	1 (6%)	4 (25%)	0 (0%)	1 (11%)	0 (0%)	10 (63%)	1 (6%)	1 (6%)	4 (25%)	0 (0%)	0 (0%)	0 (0%)
DAR	25	23	8	4 (50%)	1 (13%)	1 (13%)	2 (25%)	0 (0%)	2 (50%)	0 (0%)	5 (63%)	0 (0%)	1 (13%)	2 (25%)	0 (0%)	2 (40%)	0 (0%)
HCM	9	7	4	2 (50%)	0 (0%)	1 (25%)	1 (25%)	0 (0%)	1 (50%)	0 (0%)	2 (50%)	0 (0%)	1 (25%)	1 (25%)	0 (0%)	1 (50%)	0 (0%)
HOU	70	67	24	10 (42%)	0 (0%)	1 (4%)	13 (54%)	0 (0%)	1 (10%)	0 (0%)	10 (42%)	0 (0%)	1 (4%)	13 (54%)	0 (0%)	1 (10%)	0 (0%)
HRV	25	3	3	0 (0%)	0 (0%)	1 (33%)	2 (67%)	0 (0%)	0 (%)	0 (%)	0 (0%)	0 (0%)	1 (33%)	2 (67%)	0 (0%)	0 (%)	0 (%)
IFH	35	33	8	4 (50%)	4 (50%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	5 (63%)	3 (38%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
LOY	4	3	0	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)
LUB	11	0	0	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)
MET	19	18	9	5 (56%)	1 (11%)	0 (0%)	3 (33%)	0 (0%)	0 (0%)	0 (0%)	5 (56%)	0 (0%)	0 (0%)	4 (44%)	0 (0%)	0 (0%)	0 (0%)
MTH	44	44	13	11 (85%)	0 (0%)	1 (8%)	1 (8%)	0 (0%)	2 (18%)	0 (0%)	11 (85%)	0 (0%)	1 (8%)	1 (8%)	0 (0%)	2 (18%)	0 (0%)
OSU	4	2	0	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)
PSU	1	1	0	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)
RIH	7	6	2	1 (50%)	0 (0%)	0 (0%)	1 (50%)	0 (0%)	0 (0%)	0 (0%)	1 (50%)	0 (0%)	0 (0%)	1 (50%)	0 (0%)	0 (0%)	0 (0%)
SAN	9	9	0	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)
SHS	32	31	16	8 (50%)	1 (6%)	3 (19%)	4 (25%)	0 (0%)	1 (13%)	0 (0%)	8 (50%)	1 (6%)	3 (19%)	4 (25%)	0 (0%)	1 (13%)	0 (0%)
UAB	32	27	0	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)
UCH	15	15	4	4 (100%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	4 (100%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
UKY	29	27	0	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)
UMD	120	116	62	54 (87%)	0 (0%)	2 (3%)	5 (8%)	1 (2%)	0 (0%)	0 (0%)	54 (87%)	0 (0%)	2 (3%)	5 (8%)	1 (2%)	0 (0%)	0 (0%)
UMS	51	48	23	2 (9%)	1 (4%)	5 (22%)	15 (65%)	0 (0%)	0 (0%)	0 (0%)	3 (13%)	0 (0%)	5 (22%)	15 (65%)	0 (0%)	0 (0%)	0 (0%)
UOK	38	26	16	0 (0%)	3 (19%)	1 (6%)	12 (75%)	0 (0%)	0 (%)	0 (%)	1 (6%)	2 (13%)	1 (6%)	12 (75%)	0 (0%)	1 (100%)	0 (0%)
USC	21	18	0	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)	0 (%)
UVA	12	8	3	1 (33%)	0 (0%)	1 (33%)	1 (33%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (33%)	1 (33%)	1 (33%)	0 (0%)	0 (%)	0 (%)
UWI	33	31	14	12 (86%)	1 (7%)	0 (0%)	1 (7%)	0 (0%)	3 (25%)	0 (0%)	12 (86%)	1 (7%)	0 (0%)	1 (7%)	0 (0%)	3 (25%)	0 (0%)
VMC	52	47	13	3 (23%)	0 (0%)	4 (31%)	6 (46%)	0 (0%)	1 (33%)	0 (0%)	3 (23%)	0 (0%)	4 (31%)	6 (46%)	0 (0%)	1 (33%)	0 (0%)
WFU	22	22	7	2 (29%)	0 (0%)	0 (0%)	5 (71%)	0 (0%)	1 (50%)	0 (0%)	6 (86%)	0 (0%)	0 (0%)	1 (14%)	0 (0%)	2 (33%)	0 (0%)
TOTAL	808	714	264	146 (55%)	14 (5%)	25 (9%)	78 (30%)	1 (0%)	13 (9%)	0 (0%)	155 (59%)	9 (3%)	25 (9%)	74 (28%)	1 (0%)	14 (9%)	0 (0%)